🇺🇸 FDA

Company profile · Sponsor

BioNTech

BioNTech Manufacturing GmbH

E4442D2 · EMA pharma EU
Pipeline
23
Drugs
0
Patents
0

Quick answer

BioNTech (E4442D2) is a pharma company. headquartered in EU. listed on EMA. NovaPharmaNews links 23 pipeline programs, 0 drugs, and 0 patents to this profile..

Company facts

Ticker E4442D2
Exchange EMA
Company type pharma
Headquarters EU

Pipeline (23)

Search pipeline →

  1. BNT323, Ribodoxo® 2 mg/ml Injektionslösung, DOCETAXEL , Paclitaxel AqVida 6 mg/ml Konzentrat zur Herstellung einer Infusionslösung

    BioNTech

    Endometrial cancer

    phase 3 small molecule active

    1 trial

  2. PACLITAXEL , BNT327, PEMETREXED , CARBOPLATIN , BNT327, PEMBROLIZUMAB

    BioNTech

    Non-small cell lung cancer

    phase 3 small molecule active

    1 trial

  3. PACLITAXEL , GEMCITABINE , CARBOPLATIN , BNT327, Abraxane 5 mg/ml powder for dispersion for infusion., ERIBULIN , BNT327 Placebo

    BioNTech

    First line triple-negative breast cancer (TNBC)

    phase 3 small molecule active

    1 trial

  4. PEMBROLIZUMAB , BNT113

    BioNTech

    Unresectable head and neck squamous cell carcinoma, metastatic head and neck cancer, recurrent head and neck cancer

    phase 3 small molecule active

    1 trial

  5. Tecentriq 1 200 mg concentrate for solution for infusion, CISPLATIN , CARBOPLATIN , BNT327, ETOPOSIDE

    BioNTech

    English First-line extensive-stage small-cell lung cancer (ES-SCLC)

    phase 3 small molecule active

    1 trial

  6. BNT111, LIBTAYO 350 mg concentrate for solution for infusion.

    BioNTech

    Melanoma (Stage III and IV)

    phase 2 small molecule active

    1 trial

  7. BNT142

    BioNTech

    Solid Tumors

    phase 2 small molecule active

    1 trial

  8. BNT327 1-15, BNT327, BNT326

    BioNTech

    Advanced solid tumors

    phase 2 small molecule active

    1 trial

  9. BNT327, BNT314, BNT327 1-15

    BioNTech

    Metastatic colorectal cancer

    phase 2 small molecule active

    1 trial

  10. BNT327, BNT323

    BioNTech

    Advanced Breast Cancer Metastatic Breast Cancer

    phase 2 small molecule active

    1 trial

  11. BNT327, BNT324

    BioNTech

    Advanced Lung Cancer

    phase 2 small molecule active

    1 trial

  12. BNT327, DOCETAXEL

    BioNTech

    Non-small Cell Lung Cancer

    phase 2 small molecule active

    1 trial

  13. BNT329

    BioNTech

    Advanced Solid Cancers

    phase 2 small molecule active

    1 trial

  14. Calciumfolinat HEXAL 10 mg/ml Injektionslösung, Irinotecan HCl AqVida 20 mg/ml Konzentrat zur Herstellung einer Infusionslösung, BNT321, FLUOROURACIL, Oxaliplatin AqVida 5 mg/ml Konzentrat zur Herstellung einer Infusionslösung

    BioNTech

    Resected (R0 or R1) pancreatic ductal adenocarcinoma

    phase 2 small molecule active

    1 trial

  15. PACLITAXEL , BNT326, CARBOPLATIN , BNT327, PEMBROLIZUMAB , PEMETREXED

    BioNTech

    Non-small Cell Lung Cancer

    phase 2 small molecule active

    1 trial

  16. Watchful waiting, RO7198457 (autogene cevumeran)

    BioNTech

    Stage II/Stage III rectal cancer or Stage II (high risk)/Stage III colon cancer

    phase 2 small molecule active

    1 trial

  17. A clinical trial investigating the safety and biological activity of the antibody BNT351 in adults living without and with HIV

    BioNTech

    HIV-1 infection

    phase 1 other active

    1 trial

  18. An open-label Phase 1 study of NEO-PTC-01 in patients with advanced or metastatic melanoma

    BioNTech

    Metastatic melanoma

    phase 1 other active

    1 trial

  19. BNT211, BNT211, BNT211, BNT211

    BioNTech

    Solid Tumors

    phase 1 small molecule active

    1 trial

  20. BNT314

    BioNTech

    Advanced or metastatic malignant solid tumors

    phase 1 small molecule active

    1 trial

  21. Clinical trial evaluating the safety, tolerability, and preliminary efficacy of BNT116 alone and in combinations in patients with advanced non-small cell lung cancer

    BioNTech

    Advanced non-small cell lung cancer

    phase 1 other active

    1 trial

  22. Dose escalation trial of BNT152+153 in patients with cancer

    BioNTech

    Various solid tumors that are metastatic or unresectable

    phase 1 other active

    1 trial

  23. Safety and immune responses after vaccination with two investigational RNA-based vaccines against tuberculosis in healthy volunteers

    BioNTech

    Tuberculosis

    phase 1 other active

    1 trial

Frequently asked questions

What is BioNTech?

BioNTech (E4442D2) is a pharma company. headquartered in EU. listed on EMA. NovaPharmaNews links 23 pipeline programs, 0 drugs, and 0 patents to this profile..

What pipeline programs does BioNTech sponsor?

We track 23 ClinicalTrials.gov-linked programs for BioNTech, including BNT323, Ribodoxo® 2 mg/ml Injektionslösung, DOCETAXEL , Paclitaxel AqVida 6 mg/ml Konzentrat zur Herstellung einer Infusionslösung and 22 more. Open each program for phase, modality, NCT IDs, and indication details.

Where does BioNTech company data come from?

Profiles combine SEC EDGAR (CIK/ticker), ClinicalTrials.gov sponsor links, FDA drug records, and USPTO patent metadata. See our data sources page. This profile is for professional reference, not investment advice.